Video Library

Currently Viewing: Ted Lamson

Show more
neotract-early-study-design

NeoTract: Need, Solution, and Evidence Requirements

Ted Lamson, co-founder and CTO of NeoTract, shares his philosophy on the evidence requirements for a quality-of-life solution like the NeoTract offering.

Show more
neotract-proving-device-feasibility

NeoTract: Proving Device Feasibility

Ted Lamson, co-founder and CTO of NeoTract, describes his approach to proving the feasibility of the company’s solution in humans before making a more substantial investment in development and testing.

Show more
neotract-choosing-location

NeoTract: Choosing a Location and Investigators for Its First-in-Human Study

Ted Lamson, co-founder and CTO of NeoTract, outlines some of the key factors NeoTract considered in setting up its first-in-human study.

Show more
neotract-advantages-of-conducting-early-studies-outside

NeoTract: Advantages of Conducting Early Studies Outside the U.S.

Ted Lamson, co-founder and CTO of NeoTract, comments on how it can sometimes be beneficial to conduct early clinical work outside the U.S.

Show more
neotract-early-study-design

NeoTract: Early Study Design and Publication

Ted Lamson, co-founder and CTO of NeoTract, shares his experience and some pointer on clinical study design and devising a publication strategy.

Show more
decision-to-pursue-ce-mark-copy

NeoTract: The Decision to Pursue a CE Mark

Ted Lamson, co-founder and CTO of NeoTract, explains why and when NeoTract decided to pursue a CE Mark.

Show more
neotract-ce-mark-experience

NeoTract: CE Mark Experience

Ted Lamson, co-founder and CTO of NeoTract, describes how his company’s pursued a CE Mark.

Show more
launch-in-EU

NeoTract: Launching in Europe and Getting Value from Its CE Mark

Ted Lamson, co-founder and CTO of NeoTract, shares how and why his company undertook as selective European launch after receiving its CE Mark.

Show more
prelim-interact-with-nice

NeoTract: Preliminary Interactions with NICE

Ted Lamson, co-founder and CTO of NeoTract, explains when his company was approached by NICE and how it managed those interactions.

Show more
nice-decision-and-impact

NeoTract: The NICE Decision and Its Impact

Ted Lamson, co-founder and CTO of NeoTract, discusses his technology’s initial NICE decision and the effect it has had on the company.

Show more
pricing

NeoTract: Pricing

Ted Lamson, co-founder and CTO of NeoTract, comments on pricing for medtech products.